Avid Bioservices Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Avid Bioservices de 66.1% y 18.5% por año respectivamente. Se prevé que el BPA crezca en un 72.9% al año. Se espera que la rentabilidad financiera sea de 1.1% en 3 años.

Información clave

66.1%

Tasa de crecimiento de los beneficios

72.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.4%
Tasa de crecimiento de los ingresos	18.5%
Rentabilidad financiera futura	1.1%
Cobertura de analistas	Low
Última actualización	30 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business

Jul 27

Avid Bioservices GAAP EPS of $1.65 beats by $1.65, revenue of $31M beats by $2.04M

Jun 29

Avid Bioservices (NASDAQ:CDMO) Seems To Use Debt Quite Sensibly

May 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CDMO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
4/30/2026	206	0	0	9	3
4/30/2025	164	-12	-8	-1	5
4/30/2024	139	-20	-19	13	5
1/31/2024	137	-18	-38	13	N/A
10/31/2023	141	-12	-56	2	N/A
7/31/2023	150	-3	-93	-8	N/A
4/30/2023	149	1	-91	-13	N/A
1/31/2023	141	116	-92	-15	N/A
10/31/2022	134	119	-89	-3	N/A
7/31/2022	126	123	-48	11	N/A
4/30/2022	120	128	-47	9	N/A
1/31/2022	116	10	-9	27	N/A
10/31/2021	106	9	8	27	N/A
7/31/2021	101	6	13	27	N/A
4/30/2021	96	3	21	31	N/A
1/31/2021	81	0	10	16	N/A
10/31/2020	73	-5	5	11	N/A
7/31/2020	70	-7	2	6	N/A
4/30/2020	60	-15	2	6	N/A
1/31/2020	64	-10	5	8	N/A
10/31/2019	64	-9	4	6	N/A
7/31/2019	56	-11	-8	-7	N/A
4/30/2019	54	-10	-13	-12	N/A
1/31/2019	43	-16	-18	-15	N/A
10/31/2018	37	-24	-23	-21	N/A
7/31/2018	39	-30	-25	-21	N/A
4/30/2018	54	-25	-30	-26	N/A
1/31/2018	65	-17	-43	-40	N/A
10/31/2017	69	6	N/A	-42	N/A
7/31/2017	79	11	N/A	-34	N/A
4/30/2017	58	-3	N/A	-39	N/A
1/31/2017	59	-17	N/A	-33	N/A
10/31/2016	54	-48	N/A	-30	N/A
7/31/2016	41	-57	N/A	-40	N/A
4/30/2016	44	-1	N/A	-40	N/A
1/31/2016	35	-60	N/A	-36	N/A
10/31/2015	34	-56	N/A	-38	N/A
7/31/2015	31	-55	N/A	-41	N/A
4/30/2015	27	-54	N/A	-36	N/A
1/31/2015	24	-51	N/A	-40	N/A
10/31/2014	22	-47	N/A	-39	N/A
7/31/2014	23	-42	N/A	-33	N/A
4/30/2014	22	-36	N/A	-28	N/A
1/31/2014	20	-34	N/A	-26	N/A
10/31/2013	23	-29	N/A	-25	N/A
7/31/2013	22	-30	N/A	-29	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CDMO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CDMO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CDMO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (18.5% al año) de CDMO crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 18.5% al año) de CDMO crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de CDMO sea baja dentro de 3 años (1.1%).

Avid Bioservices Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

Consensus EPS estimates fall by 121%

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

Consensus EPS estimates fall by 139%

Price target decreased by 7.2% to US$19.25

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

Recent updates

Insufficient new directors

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices, Inc. announced delayed 10-Q filing

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Insufficient new directors

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Director recently bought US$135k worth of stock

Consensus EPS estimates fall by 121%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Independent Chairman recently bought US$191k worth of stock

Consensus EPS estimates fall by 139%

Price target decreased by 7.2% to US$19.25

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

President exercised options and sold US$254k worth of stock

Price target decreased by 11% to US$19.75

President exercised options and sold US$519k worth of stock

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Investor sentiment deteriorates as stock falls 15%

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Insider notifies of intention to sell stock

Independent Director recently sold US$142k worth of stock

Director exercised options and sold US$69k worth of stock

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings released

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

Consensus EPS estimates fall by 217%

Director exercised options and sold US$60k worth of stock

Director exercised options and sold US$57k worth of stock

Independent Director recently sold US$87k worth of stock

President exercised options and sold US$117k worth of stock

Consensus forecasts updated

Director exercised options and sold US$116k worth of stock

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023

Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Director exercised options and sold US$69k worth of stock

Consensus forecasts updated

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Avid Bioservices, Inc. to Report Q1, 2023 Results on Sep 06, 2022

Avid Bioservices, Inc., Annual General Meeting, Oct 18, 2022

President exercised options and sold US$366k worth of stock

Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Consensus EPS estimates fall by 71%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Avid Bioservices, Inc. Provides Revenue Guidance for Fiscal 2023